Background-Enhanced sarcoplasmic reticulum Ca 2+ -leak via ryanodine receptor type-2 (RyR2) contributes to the pathogenesis of atrial fibrillation (AF). Recent studies have shown that the level of RyR2 protein is elevated in atria of patients with paroxysmal AF, suggesting that microRNA-mediated post-transcriptional regulation of RyR2 might be an underlying mechanism. Bioinformatic analysis suggests that miR-106b and miR-93, members of the miR-106b-25 cluster, could bind to RyR2-3′-untranslated region and suppress its translation. Thus, we tested the hypothesis that loss of the miR-106b-25 cluster promotes AF via enhanced RyR2-mediated sarcoplasmic reticulum Ca 2+ -leak. Methods and Results-Quantitative real-time polymerase chain reaction showed that the levels of mature miR-106b, miR-93, and miR-25 were lower in atria of patients with paroxysmal AF when compared with patients in sinus rhythm.
A trial fibrillation (AF) is the most commonly encountered cardiac arrhythmia in the clinical setting and the leading cause of stroke among other morbidities and mortalities. Currently, pharmacological treatments of AF are not optimal because of an incomplete understanding of AF pathogenesis. 1 Emerging evidence suggests a central role of ryanodine receptor type-2 (RyR2) in AF development, including both initiation and maintenance of AF. 2, 3 Specifically, inappropriate diastolic Ca 2+ -release from the sarcoplasmic reticulum (SR) through RyR2 has been causally linked to both atrial ectopic activity and atrial remodeling critical for AF maintenance and progression. 2, 4 In chronic AF, hyperactivity of RyR2 has been attributed to RyR2 hyperphosphorylation caused by overactive kinases. 5 In contrast, recent studies have found that RyR2 is not hyperphosphorylated in paroxysmal AF (pAF), the earlier stage of AF before extensive structural remodeling occurs. 4, 6 Instead, these studies showed that RyR2 protein levels are upregulated in pAF and that there is an increase in SR Ca 2+leak in these patients. 4, 6 Although many biological processes could contribute to protein upregulation, we hypothesized that altered epigenetic regulation of RyR2 in pAF caused by a downregulation of microRNA (miRNA)-mediated translational repression leads to the increased SR Ca 2+ -leak and atrial arrhythmogenesis.
of mRNAs by either suppressing their translation or promoting their degradation. 7 Several studies have uncovered the role of miRNAs in cardiac diseases, such as myocardial infarction, 8 cardiac hypertrophy, 9 and AF. [10] [11] [12] However, these studies did not address the changes in pAF or investigate the regulation of RyR2 by miRNAs, despite its central role in AF pathogenesis. In this study, we identified miRNAs that are bioinformatically predicted to regulate the RyR2-3′-untranslated region (UTR) and confirmed using luciferase reporter assay that miR-93, a member of the miR-106b-25 cluster, regulates RyR2-3′UTR. We also showed that the expression of the miR-106b-25 cluster is reduced in patients with pAF, pointing to a potential causal relationship between the downregulation of this cluster and the upregulation of RyR2 protein. We directly tested this hypothesis in mice and demonstrated that miR-106b-25 ablation led to (1) increased RyR2 protein levels, (2) enhanced Ca 2+sparks frequency and SR Ca 2+ -leak in atrial myocytes, and (3) increased frequency of atrial ectopy and susceptibility to pacing-induced AF.
Methods
Detailed Methods are provided in the Data Supplement.
Human Atrial Samples
Human right atrial appendages were collected with written informed consent under protocols approved by the ethics committee of the Medical Faculty Essen, University Duisburg-Essen (12-5268-BO). Detailed characteristics of patients are provided in Table I 
Study Animals
Animal protocols were approved by the Institutional Animal Care and Use Committee of Baylor College of Medicine. miR-106b-25 homozygous knockout mice (miR-106b-25 −/− ) were purchased from The Jackson Laboratory.
Bioinformatic Identification of Candidate RyR2-Regulating MiRNAs
We used 3 established miRNA target prediction algorithms: TargetScan6.2, PITA, and microrna.org, to identify potential RyR2-regulating miRNAs. Only 13 miRNAs were predicted to target RyR2 gene by all 3 algorithms (Table II in the Data Supplement). The ranking of these 13 miRNAs from each algorithm was combined and sorted. The top 5 miRNAs based on the combined ranking were considered for further analysis (Table II in the Data Supplement).
Quantitative Real-Time Polymerase Chain Reaction
Total RNA, including miRNAs, was isolated using Direct-zol RNA MiniPrep (Zymo Research, Irvine, CA). For detection of mRNAs, reverse transcription was performed using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA). For detection of miR-NAs, reverse transcription and quantitative real-time-polymerase chain reaction were performed using a modified protocol as previously described. 13 All quantitative real-time-polymerase chain reaction reactions were performed using PerfeCTa SYBR Green FastMix (Quanta Biosciences, Gaithersburg, MD) in triplicates in 96-well plates in Mastercycler ep realplex (Eppendorf, Hamburg, Germany). Expression levels were compared using the relative CT (cycle number) method after normalization to L7. The primers used for mRNA and miRNA detection are listed in Tables IV and V in the Data Supplement, respectively. 14
Luciferase Assay
The 1437-bp 3′UTR of Homo sapiens RyR2 and 1418-bp 3′UTR of Mus musculus Ryr2 were amplified, respectively, from human and mouse cardiac cDNA libraries and subcloned into pRL-CMV 6x CXCR4 Renilla luciferase vector using forward primer 5′-CTGATGTCTAGAGCAGGAATCTTATGTCTGGAAGATG-3′ and reverse primer 5′-CTGATGGCGGCCGCGTTAAATAGTTT AATCAGAGCGGTTTTACAG-3′ for the human RyR2 and forward primer 5′-GTCGTCTCTAGATAGCATCATACCTTGATTGTCT CTG-3′ and reverse primer 5′-GTCGTCGCGGCCGCGTTAGTT AAATAGTTTAATTAGAGCCGTTTTAC-3′ for the mouse Ryr2. The putative interaction sites between miR-93 and the 3′UTRs were searched using RNAhybrid. 15 Mutagenesis was performed using QuikChangeII (Agilent Technologies, Santa Clara, CA) to disrupt these interactions using forward primer 5′-TCGACATAAAGAAAATAAAGATGTTTTTACCGGTACG TATCTTCTGCATAGCTCAACCCACA-3′ and reverse primer 5′-TGTGGGTTGAGCTATGCAGAAGATACGTACCGGTAAAAA CATCTTTATTTTCTTTATGTCGA-3′ for the human RyR2 3′UTR and forward primer 5′-GATGTAAAGAA AATAAAGGTGTTTGACCGGTACATTATCTTCTGCATA GCTCAACCCACTTATA-3′ and reverse primer 5′-TATAAGTGGGTTGAGCTATGCAGAAGATAATGTACC GGTCAAACACCTTTATTTTCTTTACATC-3′ for the mouse Ryr2 3′UTR.
HEK293 cells were seeded in 24-well plates using antibiotics-free DMEM medium (Invitrogen, Carlabad, CA) supplemented with 10% fetal bovine serum and 2 mmol/L L-glutamine. When the cells reached 50% to 90% confluency, they were cotransfected using LipoD293 (SignaGen Laboratories, Rockville, MD) and Opti-MEM (Life Technologies, Carlsbad, CA) with each of the 3′UTR Renilla luciferase constructs, the pGL3 firefly luciferase construct, and each of the following miRNA mimics: miR-25, miR-93, miR-106a, miR-106b, and nontargeting scramble (Life Technologies) used at a final concentration of 100 nmol/L. Eighteen to 24 hours after transfection, the cells were harvested and assayed using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI) according to the manufacturer's instructions. Renilla luciferase signals were normalized to the firefly luciferase signals.
Immunoblotting
Protein extraction and Western blotting were performed as previously described. 2 Briefly, mouse or human tissue lysates or SR fractions were subjected to SDS-PAGE and transferred onto polyvinyl difluoride membranes. The membranes were then incubated with antibodies in 5% milk against the following proteins: RyR2 (1:5000; MA3-916; Thermo Fisher Scientific, Houston, TX), Na + /Ca 2+ -exchanger type-1 (NCX1; 1:1000; R3F1; Swant, Bellinzona, Switzerland), calsequestrin type-2 (CSQ2; 1:1000; PA1-913; Thermo Fisher Scientific), Ca 2+ / calmodulin protein kinase II phosphorylated RyR2 at Serine2814 (pS2814; 1:1,000; custom-made), 16 and GAPDH (1:10,000; MAB-374; Millipore, Billerica, MA). Membranes were then washed in trisbuffered saline and incubated with secondary antimouse and antirabbit antibodies (both 1:10 000) conjugated, respectively, to Alexa-Fluor 680 (Life Technologies) and IR800Dye (Rockland Immunochemicals, Gilbertsville, PA). The fluorescence was visualized on an Odyssey infrared scanner (Li-Cor, Lincoln, NE), and the bands were quantified using ImageJ (National Institutes of Health, Bethesda, MD).
Telemetry ECG Recording
Mice were implanted with telemeters (Data Sciences International, New Brighton, MN) as previously described. 17 Twenty-four-hour ambulatory ECG was monitored in conscious mice at 3 months of age. Telemetry ECG recordings were analyzed using ECG-Auto software (Emka Technologies).
Intracardiac Electrophysiology
In vivo electrophysiology studies were performed in mice at 4 to 5 months of age, as previously described. 16 Additional details are provided in the Data Supplement.
Coimmunoprecipitation
Atrial lysates was prepared, and coimmunoprecipitation was performed as previously described. 3 A concentration of 1000 μg of lysates was suspended with lysis buffer: 1% CHAPS in 1000 μL RIPA buffer (pH 7.4) containing 150 mmol/L NaCl, 10 mmol/L Tis-HCl, 20 mmol/L NaF, 1 mmol/L NaVO 3 , and protease and phosphatase inhibitor cocktails (cOmplete, Mini, and PhosSTOP from Roche Applied Science, Indianapolis, IN). The samples were incubated at 4°C with 3 μL of RyR2 antibody (MA3-916; Thermo Scientific) or mouse IgG (M5284; Sigma) and rotated overnight. The next day, 50 μL of protein G beads slurry was added to each sample and further rotated at 4°C for 1 hour. The pellet was collected and washed 2× with the same RIPA buffer (except without CHAPS). Afterward, the pellet was incubated with 20 μL of loading buffer at 70°C for 10 minutes before the supernatant was used for SDS-PAGE.
Statistical Analysis
Data are presented as mean±SEM. Statistical analysis was performed using SPSS Exact Tests (IBM). To compare continuous variables with a skewed distribution, the Mann-Whitney test was applied. Fisher exact test was used to compare categorical data. Ca 2+ sparks and leak data were analyzed using R and the R packages lme4 and languageR, using linear mixed-effect models where the sparks or leak values are the dependent variable, while genotype/treatment group is set as the fixed effect and the mouse and cell (or spark for the spark parameters) are set as random effects. The Markov-chain Monte Carlo sampling or MCMC-estimated P values of these models were reported. A value of P≤0.05 was considered statistically significant.
Results

Increased RyR2 Protein Expression in Patients With pAF
Previous studies demonstrated an increased level of RyR2 protein in atrial samples from patients with pAF. 4, 6 Using the same or similar samples, RyR2 protein and mRNA levels were assessed to pinpoint the underlying mechanism of dysregulation. Increased protein levels of RyR2 were found in SR fractions of patients with pAF when compared with control patients in sinus rhythm (P<0.05; Figure 1A ), consistent with previous reports. 4, 6 In contrast, however, RyR2 mRNA levels were unchanged in pAF when compared with patients in sinus rhythm (P>0.05; Figure 1B ). This suggests a putative role for miRNA-mediated post-transcriptional regulation that normally would repress the translation of RyR2 mRNA. A bioinformatic analysis to identify candidate miRNAs was performed using 3 established miRNA target prediction algorithms (TargetScan6.2, PITA, and microrna.org). Thirteen miRNAs were predicted by all 3 algorithms to target the RyR2 3′UTR ( Table II in the Data Supplement). After sorting by a score (Rank) that takes into account of all 3 algorithms, the top 5 miRNAs (miR-93, miR-129, miR-506, miR-124, and miR-106a) were chosen for further studies ( Table II in 
MiR-106b-25 Cluster Is Downregulated in Patients With pAF
Because miRNAs negatively regulate mRNAs, we hypothesized that RyR2-regulating miRNAs would be downregulated in patients with pAF. The levels of the top 5 predicted miRNAs were, therefore, measured using quantitative realtime polymerase chain reaction in atrial samples from patients with pAF and in sinus rhythm. Only miR-93 and miR-106a were significantly downregulated in patients with pAF by 44% (P<0.01) and 53% (P<0.05), respectively, when compared with patients in sinus rhythm ( Figure 1C ). Because miR-106b and miR-25 are comembers of miR-93 in the miR-106b-25 cluster, 18 we also measured their levels in patients with pAF and found that they were also significantly downregulated in pAF samples by 38% (P<0.05) and 39% (P<0.05), respectively ( Figure 1C ). These data demonstrate that the entire miR-106b-25 cluster is downregulated in patients with pAF, which is most likely because of the downregulation of its host gene, minichromosome maintenance complex component 7 (MCM7; Figure I in the Data Supplement).
Because the expression level of miR-93 is ≈2.5-fold higher than that of miR-106a in all 4 chambers of the human heart 19 and miR-93 is the top-ranked candidate that regulates RyR2 ( Table II in 
MiR-93 Targets the RyR2 3′UTR
Computational analysis of the Homo sapiens and Mus musculus RyR2-3′UTR revealed conserved binding sites for miR-93 ( Figure 2A-2C ). To determine whether miR-93 could bind to the 3′UTR of RyR2, dual luciferase activity of RyR2-3′UTR construct was measured in the presence of miR-106b, miR-93, miR-25, miR-106a, or scramble (negative control) mimics. MiR-93 mimic significantly reduced the luciferase activity of both the human and the mouse RyR2-3′UTR (P<0.01) when compared with the scramble mimic ( Figure 2D ). Mutation of the predicted binding site on both 3′UTRs abolished this inhibitory effect of the miR-93 mimic. In addition, miR-106b (P<0.05) and miR-106a (P<0.01) mimics also reduced the luciferase activity of the mouse Ryr2-3′UTR but not of the human RyR2-3′UTR, which effect was also abolished by the mutation on the predicted binding site on mouse Ryr2-3′UTR. In contrast, miR-25 mimic had no effect on either human or mouse RyR2-3′UTR luciferase activity. Together, these results demonstrate that miR-93 negatively regulates RyR2-3′UTR, which could lead to decreased RyR2 protein expression.
MiR-106b-25 Deficiency Causes Upregulation of RyR2 Protein
To determine whether the loss of the miR-106b-25 cluster could lead to RyR2 upregulation, both RyR2 mRNA and protein levels were measured in atrial tissue of miR-106b-25 −/− mice. Consistent with patients with pAF, RyR2 mRNA levels were comparable in atria of miR-106b-25 −/− and wild-type (WT) littermates ( Figure 3A) , whereas RyR2 protein was increased by 42% in miR-106b-25 −/− atrial lysates (P<0.05; Figure 3B ). Protein levels of other major Ca 2+ -handling proteins, including Na + /Ca 2+ exchanger type-1 (NCX1), calsequestrin type-2 (CSQ2), sarcoplasmic/endoplasmic reticulum Ca 2+ -ATPase 2a (SERCA2a), and phospholamban, as well as the phosphorylation levels of RyR2 at serine (S)2814 were unchanged in miR-106b-25 −/− atria ( Figure 3C ). Interestingly, there was no change in RyR2 protein levels in the ventricles of miR-106b-25 −/− mice ( Figure II in the Data Supplement).
Immunocytochemistry experiment in atrial myocytes isolated from miR-106b-25 −/− mice demonstrated that RyR2 exhibited normal distribution patterns within the junctional SR membrane where it colocalizes with junctophilin-2 (JPH2; Figure III in the Data Supplement). This suggests that the extra RyR2 channels are proportionally distributed within the cells, most likely participating in SR Ca 2+ -release.
MiR-106b-25 Deficiency Increases Ca 2+ -Release via RyR2 Clusters
To evaluate whether the extra RyR2 channels can increase Ca 2+ -release, we measured Ca 2+ -sparks frequency in isolated atrial myocytes. Ca 2+ -sparks frequency normalized to SR Ca 2+load was increased in miR-106b-25 −/− (2.2±0.5 a.u.) when compared with WT littermates (1.0±0.2 a.u.; P<0.05; Figure 4A and 4B ). Although the amplitude ( Figure 4C) , duration, and decay of Ca 2+ -sparks (Table III in the Data Supplement) were unaltered in miR-106b-25 −/− mice, the full-width at half maximum was increased in miR-106b-25 −/− mice (1.46±0.03 μm) when compared with WT littermates (1.36±0.03 μm; P<0.05; Figure 4D ). Moreover, incubation with the RyR2 inhibitor K201 20 reduced the Ca 2+ -sparks frequency (0.7±0.2 a.u.; P<0.05) and the full-width at half maximum (1.11±0.03 μm; P<0.001) in atrial myocytes of miR-106b-25 −/− mice ( Figure 4B and 4D ). Together these findings support the notion that the increased amount of RyR2 in miR-106b-25 −/− mice resulted in larger functional RyR2 clusters on the SR.
We also analyzed the kinetics of the Ca 2+ -induced-Ca 2+ -release. We found that the Ca 2+ -transient amplitude was increased in atrial myocytes isolated from the miR-106b-25 −/− mice, while the decay constant (τ) of Ca 2+transient was unchanged ( Figure IV in the Data Supplement). The enhanced Ca 2+ -induced-Ca 2+ -release could be attributed to more SR Ca 2+ -release via either a larger RyR2 clusters or increased number of RyR2 clusters, both of which facilitates the synchronization between RyR2 clusters and lead to a greater Ca 2+ -transient amplitude. This also suggests that not only is diastolic SR Ca 2+ -leak increased but also is Ca 2+ -induced-Ca 2+ -release increased. On the contrary, the unchanged τ suggests that SERCA2a activity is unchanged with miR-106b-25 deficiency, consistent with the unchanged SERCA2a protein level in the miR-106b-25 −/− atria ( Figure 3C) .
It was previously shown that JPH2 binding to RyR2 stabilizes RyR2 and that reduced JPH2/RyR2 ratio in patients with pAF causes RyR2 hyperactivity associated with AF pathogenesis. 6 Thus, we evaluated the interaction between RyR2 and JPH2 in atrial samples of miR-106b-25 −/− mice. Coimmunoprecipitation experiment revealed that more RyR2 was pulled-down from the miR-106b-25 −/− atrial lysates ( Figure V in the Data Supplement). Despite the similar amount of JPH2 that was coimmunoprecipitated with RyR2, the ratio of JPH2/RyR2 was significantly reduced in miR-106b-25 −/− atria (P<0.01; Figure V in the Data Supplement). This finding suggests that the extra RyR2 molecules are not stabilized by JPH2 and, therefore, may be hyperactive, contributing to the increased SR Ca 2+ -leak in miR-106b-25 −/− atrial myocytes.
MiR-106b-25 Deficiency Increases Spontaneous Ca 2+ -Waves
To test whether the increased amount of RyR2 in miR-106b-25 −/− atria directly affects SR Ca 2+ -release, we measured SR Ca 2+ -leak. 2 SR Ca 2+ -leak normalized to SR Ca 2+ -load was significantly higher in miR-106b-25 −/− atrial myocytes (20.1±3.8%) when compared with WT littermates (10.5±1.4%; P<0.05; Figure 5A and 5B). In addition, preincubation of atrial myocytes with the RyR2 inhibitor K201 (1 μmol/L) for 30 minutes reduced the SR Ca 2+ -leak to 9.4±1.7% in the miR-106b-25 −/− atrial myocytes (P<0.05 versus untreated cells; Figure 5B ).
To assess whether enhanced SR Ca 2+ -leak could evoke potentially arrhythmogenic Ca 2+ -waves, the extracellular Ca 2+ -concentration was increased to 2.5 mmol/L and isoproterenol (1 μmol/L) was added to the perfusate. Under these conditions, 67% of myocytes from miR-106b-25 −/− mice (9 of 16) developed spontaneous Ca 2+ -waves, whereas this behavior was observed in only 13% of myocytes from WT littermates (2 of 16; P<0.01; Figure 5C and 5D). These data indicate that miR-106b-25 deficiency increases the incidence of proarrhythmic Ca 2+ -release events because of upregulation of RyR2 levels.
MiR-106b-25 Deficiency Promotes Ectopic Activity and an AF Substrate
To examine whether miR-106b-25 −/− mice develop spontaneous atrial arrhythmias, 24-hour ECG telemetry recordings were performed. Although no episodes of spontaneous AF were observed, an increase in premature atrial contractions were seen in the miR-106b-25 −/− (6.0±2.0 beats/h) versus WT littermates (1.0±0.4 beats/h; P<0.05; Figure 6A and 6B) . This suggests that the loss of the miR-106b-25 cluster promotes atrial ectopy in mice.
We recently showed that RyR2-mediated SR Ca 2+ -leak promotes the development of an AF substrate, including enlarged atria and slowed atrial conduction velocity permissive of AF progression. 2 Here, we found that miR-106b-25 −/− mice also exhibited an increased atrial weight normalized to tibia length (0.47±0.02 mg/mm) compared with WT littermates (0.33±0.03 mg/mm; P<0.01; Figure 6C and 6D). This suggests that the loss of the miR-106b-25 cluster may also lead to the development of an AF-maintaining substrate, which is not secondary to the impaired ventricular function ( Figure VI 
MiR-106b-25 Deficiency Increases the Susceptibility to AF
To determine whether miR-106b-25 −/− mice are more prone to AF development, programmed intracardiac stimulation was performed. Baseline electrophysiological parameters, including heart rate, QRS, QTc, sinus node recovery time, and atrial refractory period, were similar in miR-106b-25 −/− and WT. Upon rapid atrial pacing, 75% of miR-106b-25 −/− mice developed reproducible AF (6 of 8) compared with only 12.5% of WT littermates (1 of 8; P<0.05; Figure 7A , 7B, and 7D). To test whether the increased AF inducibility was because of enhanced SR Ca 2+ -release via RyR2, we repeated AF induction in miR-106b-25 −/− mice 15 to 20 minutes after injected with the RyR2 inhibitor K201 (10 mg/kg, IP). 20 K201 indeed reduced the incidence of pacing-induced AF to 14.3% (1 of 7; P<0.05 versus before K201 injection; Figure 7C and 7D) . Altogether, our data support the hypothesis that miR-106b-25 deficiency leads to atrial arrhythmogenesis via enhanced RyR2-mediated SR Ca 2+ -release.
Discussion
Our study suggests a novel molecular mechanism underlying AF development, namely defective epigenetic regulation of RyR2 expression as a result of reduced miR-106b-25 cluster activity. Our data revealed that the loss of the miR-106b-25 cluster lead to the upregulation of RyR2 protein levels and proarrhythmic SR Ca 2+ -release, which were associated with an increased incidence of atrial ectopy. The impaired miRNAmediated RyR2 dysregulation increased AF susceptibility in mice and may contribute to the pathogenesis of paroxysmal AF in humans. 
Emerging Role of miRNA-Mediated Epigenetic Regulations in AF Development
Epigenetic regulations are emerging as important mechanisms underlying the development of cardiac arrhythmias. 21 Recent advancement in DNA and RNA sequencing technologies has enabled epigenome mapping and provided novel insights into the abnormal expressions of key proteins implicated in arrhythmogenesis. 22, 23 Several studies have demonstrated the role of miRNAs in AF pathogenesis. 11, 12, 24 For example, miR-328, 11 miR-499, 25 and miR-26 12 have been associated with AF development via regulating L-type Ca 2+ -channel, small-conductance Ca 2+ -activated potassium channel 3, and inward-rectifier potassium current, respectively. In addition, miR-133, miR-590, and miR-21 have been shown to promote atrial fibrosis associated with AF. 24, 26 Our study revealed that an entire miRNA cluster, the miR-106b-25 cluster, is downregulated in patients with pAF, and that genetic ablation of this cluster promoted arrhythmogenesis through increased RyR2-mediated Ca 2+release. Interestingly, a recent study by Wahlquist et al 27 showed that enhanced miR-25-mediated regulation of SERCA2a contributes to the reduced cardiac contractility in heart failure. Although the suppressed SERCA2a-mediated Ca 2+ -reuptake is closely related to the development of heart failure, 28, 29 its role in the pathogenesis of AF has not been clearly defined. Moreover, in our study, we found that only miR-93, but not miR-25, regulates RyR2-3′UTR, suggesting that miR-93 is the main player within the miR-106b-25 cluster that regulates RyR2 Ca 2+ -release. Finally, in the study by Wahlquist et al, 27 miR-25 was found to be upregulated in patients with heart failure, whereas the entire miR-106b-25 cluster was found to be downregulated in patients with pAF in the present study ( Figure 1C ). Despite the differences, these findings highlight the importance of this cluster in regulating Ca 2+ -homeostasis and suggest potential coregulation, the mechanism of which would require additional studies.
Novel Epigenetic Mechanism Underling RyR2 Hyperactivity in AF
Many studies have demonstrated that spontaneous SR Ca 2+ -release via RyR2 can cause delayed afterdepolarizations, 16 which may constitute the cellular correlate of focal atrial activity in vivo. We have shown that mice with dysfunctional RyR2 channels are more susceptible to pacing-induced AF, which is associated with delayed afterdepolarizations -mediated triggered activity. 5 Recently, we discovered that RyR2-mediated SR Ca 2+ -leak drives atrial remodeling leading to the development of a substrate permissive of AF development. 2 Thus, RyR2-mediated Ca 2+release plays an essential role in both the initiation and the perpetuation of AF.
Evidence suggests that altered post-translational modifications (eg, phosphorylation 5 and nitrosylation 30 ) along with aberrant protein-protein interactions mediated by the binding partners (eg, FKBP12.6 31 and JPH2 6 ) are responsible for the hyperactivity of RyR2 channels in cardiac diseases.
Our recent studies and current findings revealed a prominent upregulation of RyR2 in patients with pAF 4,6 and identified a novel mechanism contributing to RyR2 hyperactivity in AF, suggesting that altered miRNA-mediated regulations of RyR2 could be an important epigenetic mechanism in AF pathogenesis.
The mechanisms underlying the arrhythmogenic Ca 2+release because of the miR-106b-25 deficiency could include (1) the extra RyR2 molecules are not stabilized by its binding partners, such as JPH2, leading to a hyperactive RyR2 channel itself; (2) the increased amount of RyR2 channels could form larger cluster to release more Ca 2+ during each opening; (3) the synchronization between RyR2 clusters may be improved because of a possibly reduced distance between clusters; and (4) the propensity of diastolic Ca 2+ to activate the NCX channel is ultimately increased. One or all of the mechanisms mentioned above could increase the arrhythmogenic SR Ca 2+ -release and thereby increase the AF susceptibility.
Therapeutic Implications
The most important challenge in AF management is finding a way to forestall the progression of the AF substrate (ie, to break the "AF begets AF" downward spiral). Our recent study demonstrated that inhibition of the RyR2mediated SR Ca 2+ -leak could prevent the progression from pAF to persistent long-lasting AF. 2 Efforts are underway to develop effective compounds to correct RyR2 hyperactivity in various cardiac diseases. 32 On the other hand, our study provides a novel therapeutic approach aimed at normalizing the protein homeostasis using miRNAs as opposed to ion channel blockers, which are suboptimal and sometimes paradoxically proarrhythmogenic. 1 Additional studies are needed to evaluate specifically whether miR-93 mimic can reduce AF susceptibility by downregulating RyR2 expression and thereby correct SR Ca 2+ -leak in mouse models of AF and ultimately in patients with AF.
Limitations
Although we have found that the host gene of miR-106b-25 cluster, MCM7, is downregulated in patients with pAF, additional studies are needed to establish the mechanistic regulation causing this dysregulation. Moreover, functional alterations in miR-106b-25 −/− are confined to atria not to ventricles, despite that the miR-106b-25 cluster is missing in entire cardiac tissue. In line with these current observations, a few recent studies also have shown the similar findings. 2, 3, 6 Additional studies are needed to delineate the mechanisms underlying the differential responses in atria and ventricle.
Conclusions
Our study suggests that abnormal miR-106b-25 regulation of RyR2 expression is one potential molecular mechanism involved in the arrhythmogenesis in both mice and patients with paroxysmal AF. Targeting miRNAs may constitute a novel therapeutic strategy to correct the potentially arrhythmogenic SR Ca 2+ -leak in patients with pAF. miR-93 mimic may, therefore, constitute a novel therapeutic strategy in treating pAF associated with RyR2 hyperactivity.
